Trade Generation Bio Co. - GBIO CFD

About Generation Bio Co

Generation Bio Co. is genetic medicines to provide treatments of rare and prevalent diseases. The Company through its non-viral genetic medicine platform, is engaged in developing genetic medicines to provide genetic payloads, which include large and multiple genes to a range of cell types across a range of diseases. It is comprised of three component technologies: ceDNA, ctLNP and ceDNA manufacturing process. ceDNA is an engineered, double-stranded, linear, covalently closed-ended deoxyribonucleic acid (DNA) construct, which includes the gene of interest and associated regulatory sequences. It has produced ceDNA constructs of approximately eight kilobases. Its ctLNP delivery system builds upon clinically validated lipid nanoparticles and is designed to allow for repeat dosing of a genetic payload without stimulating an immune response, such as antibody production. Its ceDNA manufacturing process uses its own cell-free rapid enzymatic synthesis (RES) to produce ceDNA.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Generation Bio Co revenues was not reported. Net loss increased 48% to $119.2M. Higher net loss reflects alancing val increase of 39% to $51M (expense), Labor & Related Expenses in R&D increase of 43% to $24.9M (expense), Stock-based Compensation in R&D increase from $4.3M to $9.3M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$1.74 to -$2.12.